ArticleMikrochimica acta2025
Early warning of drug-induced cardiotoxicity: quantitative determination of Mfn2 biomarker via electrochemical immunosensing technology.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in optical and electrochemical aptasensors for tumor biomarker alpha-fetoprotein.Mikrochimica acta · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced cardiotoxicity (DIC) poses a significant challenge in both drug development and clinical practice, Making early and accurate assessment crucial. Existing studies have shown that mitochondrial fusion mediated by mitochondrial fusion protein 2 (Mfn2) is closely associated with DIC, and that upregulation of Mfn2 reduces drug-induced cardiomyocyte damage and apoptosis, suggesting that Mfn2 could be a potential biomarker for early warning assessment of DIC. Due to the defects of cumbersome operation, limited sensitivity, high cost, and difficulty in popularization of existing detection technologies, this study pioneers a novel electrochemical immunosensor for highly sensitive Mfn2 detection using a composite sensing substrate of MXene-derived sodium titanate nanorods and multi-walled carbon nanotubes (M-NTO-MWCNT). This technology enables early warning and assessment of drug-induced cardiotoxicity. The M-NTO component, with its unique nanorod structure, abundant active sites, and high surface area, significantly enhances sensitivity and provides abundant antibody immobilization sites. Meanwhile, MWCNTs improve electron transfer efficiency and selectivity due to their superior conductivity and interconnected network. Under optimized conditions, the sensor achieves a detection Limit as low as 1.85 ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.